Citigroup analyst Jason Bazinet maintains Warner Bros.Discovery (NASDAQ:WBD) with a Buy and lowers the price target from $40 to $29.
Detailed Data From Phase II Crenezumab Alzheimer’s Prevention Initiative Study In Autosomal Dominant Alzheimer’s Disease Presented At AAIC; Says Crenezumab Was Safe And Well Tolerated With No Cases Of ARIA-E Observed During The Up To Eight-Year Study
Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year study
As previously reported, numerical differences favoring crenezumab over placebo were confirmed across the
